SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-23-021287
Filing Date
2023-06-14
Accepted
2023-06-14 17:18:38
Documents
57
Period of Report
2023-04-30

Document Format Files

Seq Description Document Type Size
1 form10-q.htm   iXBRL 10-Q 1015805
2 ex10-1.htm EX-10.1 304943
3 ex31-1.htm EX-31.1 17231
4 ex31-2.htm EX-31.2 17146
5 ex32-1.htm EX-32.1 7053
6 ex32-2.htm EX-32.2 6875
  Complete submission text file 0001493152-23-021287.txt   5220883

Data Files

Seq Description Document Type Size
7 XBRL SCHEMA FILE bctx-20230430.xsd EX-101.SCH 31859
8 XBRL CALCULATION FILE bctx-20230430_cal.xml EX-101.CAL 35455
9 XBRL DEFINITION FILE bctx-20230430_def.xml EX-101.DEF 191141
10 XBRL LABEL FILE bctx-20230430_lab.xml EX-101.LAB 265412
11 XBRL PRESENTATION FILE bctx-20230430_pre.xml EX-101.PRE 235096
51 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 860259
Mailing Address 3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR WEST VANCOUVER A1 V7T 2X1
Business Address 3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR WEST VANCOUVER A1 V7T 2X1 (604) 921-1810
BriaCell Therapeutics Corp. (Filer) CIK: 0001610820 (see all company filings)

IRS No.: 000000000 | State of Incorp.: A1 | Fiscal Year End: 0731
Type: 10-Q | Act: 34 | File No.: 001-40101 | Film No.: 231015051
SIC: 2834 Pharmaceutical Preparations